Smith & Nephew PLC header image

Smith & Nephew PLC

SNN

Equity

ISIN null / Valor 1111046

CTA NASDAQ OMX Stock Exchange (2026-10-09)
USD 27.24+1.04%

Smith & Nephew PLC
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Smith & Nephew PLC is a global medical technology company that develops and manufactures a wide range of clinical devices and solutions for orthopaedics, advanced wound management, sports medicine, and ear, nose, and throat (ENT) procedures. The company’s orthopaedics division produces implants for hip and knee joint replacements, along with trauma products designed to stabilize fractures and correct bone deformities, while also incorporating robotics-assisted technologies to support surgical precision. Its advanced wound management offerings cover a variety of products for treating both acute and chronic wounds, including conditions such as diabetic and pressure ulcers, burns, and post-operative complications. In addition, the sports medicine and ENT portfolios provide instruments and implants for minimally invasive soft tissue repairs and various ENT procedures. Overall, Smith & Nephew leverages these diversified capabilities to address a broad spectrum of clinical needs within the healthcare sector.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-23.7%1Y
14.6%3Y
-20.4%5Y

Performance

28.4%1Y
65.3%3Y
53.4%5Y

Volatility

Market cap

11573 M

Market cap (USD)

Daily traded volume (Shares)

982,902

Daily traded volume (Shares)

1 day high/low

24.76 / 24.55

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

CG Oncology Inc
CG Oncology Inc CG Oncology Inc Valor: 131996952
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.89%USD 63.82
Denali Therapeutics Inc
Denali Therapeutics Inc Denali Therapeutics Inc Valor: 39149539
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.18%USD 19.45
Essity AB
Essity AB Essity AB Valor: 36851944
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.69%SEK 263.70
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.48%USD 65.35
Agenus Inc
Agenus Inc Agenus Inc Valor: 134326284
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.72%USD 7.67
Tempus AI Inc
Tempus AI Inc Tempus AI Inc Valor: 135855934
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.38%USD 70.93
Concentra Group Holdings Parent Inc
Concentra Group Holdings Parent Inc Concentra Group Holdings Parent Inc Valor: 136105334
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.58%USD 37.19
Lineage Inc
Lineage Inc Lineage Inc Valor: 136372357
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.03%USD 34.43
Helen of Troy Ltd
Helen of Troy Ltd Helen of Troy Ltd Valor: 938381
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.15%USD 26.51
BioVersys AG
BioVersys AG BioVersys AG Valor: 21036264
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%CHF 26.50